Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1319-1326

  Tängdén, Thomas ^a   Adler, Marlen ^a   Cars, Otto ^a   Sandegren, Linus ^a   Löwdin, Elisabeth ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

ESBLs; Outer membrane porins; Resistance

Indexed keywords

CARBAPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F; OUTER MEMBRANE PROTEIN REGULATOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GENE MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION;

ESBLS; OUTER MEMBRANE PORINS; RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; KINETICS; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION; PORINS; TRANS-ACTIVATORS;

EID: 84884754920     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt044     Document Type: Article

References (21)

1. Rodriguez-Bano J, Navarro MD, Romero L et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum b-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008; 14: 180-3.
2. Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-b-lactamase-producing Gram-negative organisms. J Antimicrob Chemother 2010; 65: 1510-3.
3. Dalgic N, Sancar M, Bayraktar B et al. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum b-lactamaseproducing bacteria in children. Scand J Infect Dis 2011; 43: 339-43.
4. Hawser SP, Bouchillon SK, Lascols C et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum b-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect 2012; 18: 253-9.
5. Hawser SP, Bouchillon SK, Lascols C et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother 2011; 55: 3917-21.
6. Jacoby GA, Mills DM, Chow N. Role of b-lactamases and porins in resistance to ertapenem and other b-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 3203-6.
7. Hernandez-Alles S, Conejo M, Pascual A et al. Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of Klebsiella pneumoniae. J Antimicrob Chemother 2000; 46: 273-7.
8. Woodford N, Dallow JW, Hill RL et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29: 456-9.
9. Adler M, Anjum M, Andersson DI et al. Influence of acquired b-lactamases on the evolution of spontaneous carbapenem resistance in Escherichia coli. J Antimicrob Chemother 2013; 68: 51-9.
10. Yoshida T, Qin L, Egger LA et al. Transcription regulation of ompF and ompC by a single transcription factor, OmpR. J Biol Chem 2006; 281: 17114-23.
11. Poirel L, Heritier C, Spicq C et al. In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol 2004; 42: 3831-3.
12. Lartigue MF, Poirel L, Poyart C et al. Ertapenem resistance of Escherichia coli. Emerg Infect Dis 2007; 13: 315-7.
13. Yang Q, Wang H, Sun H et al. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob Agents Chemother 2010; 54: 573-7.
14. Lowdin E, Odenholt I, Bengtsson S et al. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrob Agents Chemother 1996; 40: 2478-82.
15. Gustafsson I, Lowdin E, Odenholt I et al. Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrob Agents Chemother 2001; 45: 2436-0.
16. Majumdar AK, Musson DG, Birk KL et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-11.
17. Cars O, Henning C, Holm SE. Penetration of ampicillin and dicloxacillin into tissue cage fluid in rabbits: relation to serum and tissue protein binding. Scand J Infect Dis 1981; 13: 69-74.
18. Keren I, Kaldalu N, Spoering A et al. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 2004; 230: 13-8.
19. Livermore DM, Oakton KJ, Carter MW et al. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent b-lactamases. Antimicrob Agents Chemother 2001; 45: 2831-7.
20. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-44.
21. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemaseproducing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4.